Myriad Genetics, Inc. Board of Directors

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Mr. Paul J. Diaz J.D.

Mr. Paul J. Diaz J.D.

CEO, President & Director

Dr. Kevin Richard Haas Ph.D.

Dr. Kevin Richard Haas Ph.D.

Chief Technology Officer

Mr. Scott J. Leffler

Mr. Scott J. Leffler

Chief Financial Officer

Mr. Matthew Scalo

Mr. Matthew Scalo

Senior Vice President of Investor Relations

Mr. Samraat S. Raha

Mr. Samraat S. Raha

Chief Operating Officer

Mr. Mark S. Verratti

Mr. Mark S. Verratti

Chief Commercial Officer

Dr. Dale Muzzey Ph.D.

Dr. Dale Muzzey Ph.D.

Chief Scientific Officer

Mr. Glenn Farrell

Mr. Glenn Farrell

Senior VP & Chief Marketing Officer

Ms. Jennifer L. Fox

Ms. Jennifer L. Fox

Chief Legal Officer

Ms. Natalie Munk

Ms. Natalie Munk

Principal Accounting Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.